Aflibercept 15 November 2024 | EU | Sandoz Aflibercept Biosimilars EU Approved & Formycon/Klinge Biosims...
Pearce IP BioBlast® for the week ending 15 November 2024
read more
Pearce IP BioBlast® for the week ending 08 November 2024
Aflibercept 30 October 2024 | US | Amgen Launches Aflibercept in the US, Prepares to Launch Ustekinumab &...
Pearce IP BioBlast® for the week ending 01 November 2024
Benralizumab 28 October 2024 | EU | New Indication Alert: AstraZeneca’s Fasenra® (Benralizumab) EU-Approved for EGPA...
Pearce IP BioBlast® for the week ending 25 October 2024
Aflibercept 23 October 2024 | Biocon Switching Study for Aflibercept Confirms Safety & Efficacy On 23 October...
Full Court Clarifies and Recalibrates the Obviousness Test for “Pre-Raising the Bar” Patents
Sandoz has triumphed in its appeal regarding the validity of two of Bayer’s Australian Xarelto® (rivaroxaban) patents. On 23 October 2024, the Full Court unanimously overturned Justice Rofe’s decision of 2 November 2023, holding that the two Bayer patents lack an inventive step in light of the common general knowledge taken together with a prior art patent specification. The parties have been given until 4 November to propose orders giving effect to the Full Court’s decision.
Pearce IP BioBlast® for the week ending 18 October 2024
Aflibercept 18 October 2024 | Regeneron Announces 3-Year Results for High Dose Eylea® (Aflibercept) On 18 October...
Pearce IP BioBlast® for the fortnight ending 11 October 2024
Aflibercept 8 October 2024 | AU | Bayer’s High Dose Eylea® (Aflibercept) PFS Approved in Australia On 8 October 2024,...
Pearce IP BioBlast® for the week ending 27 September 2024
Aflibercept 23 September 2024 | Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar On 23 September...
Pearce IP BioBlast® for the week ending 20 September 2024
Aflibercept 19 September 2024 | EU | Sandoz & Samsung Bioepis/Biogen Aflibercept Biosimilars Recommended in Europe...
When things go wrong: “Obvious Mistake” Results in CRISPR Patent Application Amendment
The battle to claim the earliest valid patent rights to CRISPR gene-editing technology has been fought around the world. In Australia, the most protracted dispute…
Pearce IP BioBlast® for the week ending 13 September 2024
Aflibercept 13 September 2024 | KR | Alteogen Submits Application for Biosimilar Aflibercept in Korea On 13 September...
Pearce IP BioBlast® for the fortnight ending 06 September 2024
Adalimumab 1 September 2024 | AU | Pfizer’s Biosimilar Adalimumab PBS-Listed in Australia On 1 September 2024, the PBS...
Pearce IP BioBlast® for w/e 16 August 2024
16 August 2024 | AU | Janssen Sues Samsung Bioepis for Patent Infringement in Australian Court On 16 August 2024,...
Pearce IP BioBlast® for w/e 09 August 2024
9 August 2024 | Sandoz Reports Q2/24 and Half Year Financial Results - 37% Biosimilar Growth On 9 August 2024, Sandoz...
Pearce IP BioBlast® for w/e 02 August 2024
2 August 2024 | AU | Novo Nordisk Launches Wegovy® (Semaglutide) in Australia On 2 August 2024, Australia’s...
Pearce IP BioBlast® for w/e 26 July 2024
26 July 2024 | EU | New Indication Alert: EU Approves AbbVie’s Skyrizi® (Risankizumab) for UCOn 26 July 2024, AbbVie...